^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IL13 elevation

i
Other names: IL13, Interleukin 13, IL-13, P600, Interleukin-13, MGC116786, MGC116788, MGC116789, ALRH, BHR1, Bronchial Hyperresponsiveness-1 (Bronchial Asthma), Allergic Rhinitis, NC30
Entrez ID:
over1year
HMB: Precision Medicine and Physical Function (clinicaltrials.gov)
P=N/A, N=25, Recruiting, University of North Carolina, Chapel Hill | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
IL10 elevation • IL13 elevation • IL4 elevation
almost2years
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways. (PubMed, Clin Cancer Res)
Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.
Journal • Adverse events • Checkpoint inhibition
|
IFNG (Interferon, gamma) • IL17A (Interleukin 17A) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
IL13 elevation
almost2years
Highly Pathogenic PRRSV Upregulates IL-13 Production through Nonstructural Protein 9 mediated Inhibition of N6-Methyladenosine(m6A) Demethylase FTO. (PubMed, J Biol Chem)
Furthermore, we found that the residues Asp567, Tyr586, Leu593, and Asp595 were essential for nsp9 to induce IL-13 production via attenuation of FTO expression. These insights delineate PRRSV nsp9's role in FTO-mediated IL-13 release, advancing our understanding of PRRSV's impact on host immune and inflammatory responses.
Journal
|
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • IL13 (Interleukin 13)
|
FTO expression • IL13 elevation
almost2years
Zhuyu Pills promote polarization of macrophages toward M2 phenotype to prevent atherosclerosis via PPARγ/NF-κB signaling pathway (PubMed, Zhongguo Zhong Yao Za Zhi)
Compared with the model group, low-, medium-, and high-dose Zhuyu Pills and atorvastatin calcium lowered the TC, TG, and LDL-C levels, elevated the HDL-C level, reduced the plaque area in a concentration-dependent manner, lowered the TNF-α and IL-6 levels, elevated the IL-4 and IL-13 levels, up-regulated the mRNA and protein levels of PPARγ and Arg-1, and down-regulated the mRNA and protein levels of NF-κB and iNOS in the aorta(P<0.05 or P<0.01). In conclusion, Zhuyu Pills may play an anti-atherosclerosis role by regulating PPARγ/NF-κB signaling pathway, inhibiting the polarization of macrophages toward the M1 phenotype, promoting the polarization of macrophages toward the M2 phenotype, and improving the inflammatory microenvironment of macrophages.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • APOE (Apolipoprotein E) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
|
IL13 elevation
2years
VEGF and EGFR signaling pathways are involved in the baicalein attenuation of OVA-induced airway inflammation and airway remodeling in mice. (PubMed, Respir Res)
Baicalein attenuates airway inflammation and airway remodeling through inhibition of VEGF and EGFR signaling pathways in an OVA-induced asthma mouse model. This will provide a new basis for the development of baicalein as a treatment for asthma and highlights the potential of network pharmacology and molecular docking in drug discovery and development.
Preclinical • Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • MAPK1 (Mitogen-activated protein kinase 1) • MMP9 (Matrix metallopeptidase 9) • IL13 (Interleukin 13) • MAPK3 (Mitogen-Activated Protein Kinase 3)
|
IL13 elevation
2years
HMB: Precision Medicine and Physical Function (clinicaltrials.gov)
P=N/A, N=25, Recruiting, University of North Carolina, Chapel Hill | Not yet recruiting --> Recruiting
Enrollment open
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
IL10 elevation • IL13 elevation • IL4 elevation
over2years
New trial
|
IL13 (Interleukin 13) • AHSG (Alpha 2-HS Glycoprotein)
|
IL13 elevation
over2years
Targeting the translationally controlled tumor protein by a monoclonal antibody improves allergic airway inflammation in mice. (PubMed, Biomed Pharmacother)
In addition, JEW-M449 significantly attenuated the degree of goblet cell hyperplasia and mucus secretion. Our results demonstrate that specific targeting of the flexible loop of TCTP is a potent strategy for treating airway inflammatory diseases.
Preclinical • Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
IL13 elevation
over2years
A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment. (PubMed, Sci Rep)
To augment ATRA's anti-tumorigenicity without promoting its pro-tumorigenic potential, an RARγ agonist (IRX4647) was used since it regulates T cell biology...Yet, RARα antagonist (IRX6696)-treatment with anti-PD-L1 did not repress syngeneic lung cancer growth. Together, these findings provide a rationale for a clinical trial investigating an RARγ agonist to augment check point blockade response in cancers.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • RARA (Retinoic Acid Receptor Alpha) • CD4 (CD4 Molecule) • IL13 (Interleukin 13) • IL5 (Interleukin 5)
|
PD-L1 expression • IL13 elevation
almost3years
Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab. (ASCO 2023)
P2 | "Among patients with advanced nccRCC or sccRCC, a baseline high systemic inflammatory state and high circulating VEGF-A are associated with worse outcomes after treatment with atezolizumab and bevacizumab. High levels of intratumor terminally exhausted CD8+ T cells were associated with worse PFS. These results highlight the importance of an integrative approach to explore biomarkers of response in advanced variant histology RCC which may inform future therapeutic approaches."
Clinical
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL13 (Interleukin 13)
|
VEGFA elevation • IL13 elevation
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
over3years
Interleukin 13 participates in terminal differentiation of esophageal squamous cell carcinoma cells. (PubMed, J Gastrointest Oncol)
In summary, our study suggests that IL-13 might improve the prognosis of ESCC by promoting the terminal differentiation of ESCC cells. This may offer potential new therapeutic target for early treatment of ESCC.
Journal
|
IL13 (Interleukin 13)
|
IL13 elevation
almost4years
Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of Diffuse large B-cell lymphoma. (PubMed, Hematol Oncol)
In vitro, when lymphoma cells co-cultured with peripheral blood monocytes of healthy controls, metformin down-regulated both IL-13 level and Treg cell ratio, in consistent with the decreased serum IL-13 levels of patients after 6 months of metformin maintenance therapy in the high IL-13 group...In vitro, when lymphoma cells co-cultured with peripheral blood monocytes of healthy controls, metformin down-regulated both IL-13 level and Treg cell ratio, in consistent with the decreased serum IL-13 levels of patients after 6 months of metformin maintenance therapy in the high IL-13 group. Taken together, pretreatment serum IL-13 level is related to the immunosuppressive microenvironment and poor clinical outcome of DLBCL patients and could be targeted by metformin, thus providing a new therapeutic strategy in treating DLBCL with high serum IL-13 levels.
Journal • IO biomarker
|
CCR4 (C-C Motif Chemokine Receptor 4) • IL2 (Interleukin 2) • CCL19 (C-C Motif Chemokine Ligand 19) • IL13 (Interleukin 13)
|
IL2 elevation • IL13 elevation
|
metformin